Adult Polycystic Kidney Disease and Insurance: A Case Study in Genetic Heterogeneity

North American Actuarial Journal

Volumn 11, Issue 1, 2007, Pages 90-118

  Gutiérrez, Cristina ^a   Macdonald, Angus S ^b  

^a Economic Analysis Unit   (Mexico)

^b HERIOT WATT UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 38649101987     PISSN: 10920277     EISSN: None     Source Type: Journal    
DOI: 10.1080/10920277.2007.10597439     Document Type: Article

References (35)

1. ABBOT, K., and L. AGODOA. 2002a. Polycystic Kidney Disease at End-Stage Renal Disease in the United States: Patient Characteristics and Survival. Clinical Nephrology 57(3): 208-14.
2. ABBOT, K., and L. AGODOA. 2002b. Polycystic Kidney Disease in Patients on the Renal Transplant Waiting List: Trends in Hematocrit and Survival. BioMed Central Nephrology 3(7): 1471-76.
3. Abi. 1999. Genetic Testing: ABI Code of Practice (Revised August 1999). London: Association of British Insurers.
4. Anzdata. 2002. Annual Report 2001. Adelaide, Australia and New Zealand Data Registry.
5. Benjamin, B., and J. H. Pollard. 1980. The Analysis of Mortality and Other Actuarial Statistics. London: Heinemann.
6. Churchill, D., J. Bear, J. Morgan, R. Payne, P. Mcmanamon, and H. Gault. 1984. Prognosis of Adult Onset Polycystic Kidney Disease Re-evaluated. Kidney International 26: 190-93.
7. Dalgaard, O. 1957. Bilateral Polycystic Disease of the Kidneys: A Follow-Up of Two Hundred and Eighty Four Patients and Their Families. Acta Medica Scandinavica S328: 1-255.
8. Daykin, C. D., D. A. Akers, A. S. Macdonald, T. Mcgleenan, D. Paul, and P. J. Turvey. 2003. Genetics and Insurance—Some Social Policy Issues (with Discussions). British Actuarial Journal 9: 787-874.
9. Dinani, A., D. Grimshaw, N. Robjohns, S. Somerville, A. Spry, and J. Staffurth. 2000. A Critical Review. Report of the Critical Illness Healthcare Study Group. Paper presented to the Staple Inn Actuarial Society, London, U.K.
10. Fitzpatrick, P., V. Torres, W. Charboneau, K. Offord, K. Holley, and H. Zincke. 1990. Long-Term Outcome on Renal Transplantation in Autosomal Dominant Polycystic Kidney Disease. American Journal of Kidney Diseases 15(6): 535-43.
11. Florijn, K., P. Chang, F. Van Der Woude, H. Van Bockel, and J. Van Saase. 1994. Long-Term Cardiovascular Morbidity and Mortality in Autosomal Dominant Polycystic Kidney Disease Patients after Renal Transplantation. Transplantation 57(1): 73-81.
12. Gabel, H., and H. Brynger. 1980. Renal Transplantation in Patients with Polycystic Kidney Disease in Gothenburg. Scandinavian Journal of Urololgy and Nephrology, Suppl. 54: 76-78.
13. Gabow, P., M. Johnson, W. Kaehny, W. Kimberling, D. Lezotte, I. Duley, and R. Jones. 1992. Factors Affecting the Progression of Renal Disease in Autosomal Dominant Polycystic Kidney Disease. Kidney International 41: 1311-19.
14. Gui, E. H., and A. S. Macdonald. 2003. Should Multiple Endocrine Neoplasia Be an Insurance Problem or Not? Research Report No. 03/2, Genetics and Insurance Research Centre, Heriot-Watt University.
15. Gutiérrez, M. C., and A. S. Macdonald. 2003. Adult Polycystic Kidney Disease and Critical Illness Insurance. North American Actuarial Journal 7(2): 93-115.
16. Gutiérrez, M. C., and A. S. Macdonald. 2004. Huntington’s Disease, Critical Illness Insurance and Life Insurance. Scandinavian Actuarial Journal, 279-313.
17. Hadimeri, H., G. Norden, S. Friman, and G. Nyberg 1997. Autosomal Dominant Polycystic Kidney Disease in a Kidney Transplant Population. Nephrology, Dialysis and Transplantation 12: 1431-36.
18. Harris, S., and E. Brown. 1998. Patients Surviving More than 10 Years on Haemodialysis: The Natural History of the Complications of Treatment. Nephrology Dialysis Transplantation 13: 1226-33.
19. Hateboer, N., N. Bogdanova, M. Dijk, E. Coto, A. Saggar-Malik, J. San Millan, R. Torra, D. Ravine, and M. Breuning For The European Pkd1-Pkd2 Study Group. 1999. Comparison of Phenotypes of Polycystic Kidney Disease Types 1 and 2. European PKD1-PKD2 Study Group. Lancet 353: 103-7.
20. Hoem, J. M. 1988. The Versatility of the Markov Chain as a Tool in the Mathematics of Life Insurance. Transactions of the 23rd International Congress of Actuaries, Helsinki, 8: 171-202.
21. Johnson, A., and P. Gabow. 1997. Identification of Patients with Autosomal Dominant Polycystic Kidney Disease at Highest Risk of End-Stage Renal Disease. Journal of Medical Genetics 34: 827-30.
22. MACDONALD, A. S. 2003a. Genetics and Insurance: What Have We Learned So Far? Scandinavian Actuarial Journal 324-48.
23. MACDONALD, A. S. 2003b. Moratoria on the Use of Genetic Tests and Family History for Mortgage-Related Life Insurance. British Actuarial Journal 9: 217-37.
24. Macdonald, A. S. 2004. Genetics and Insurance. In Encyclopaedia of Actuarial Science, ed. J. L. Teugels and B. Sundt. Chichester: John Wiley. 2: 769-78.
25. Mcdonald, S., and G. Russ 2002. Survival of Recipients of Cadaveric Kidney Transplants Compared with Those Receiving Dialysis Treatment in Australia and New Zealand, 1991-2001. Nephrology Dialysis Transplantation 17: 2212-19.
26. Meier-Kriesche, H., A. Ojo, F. Port, J. Arndorfer, D. Cibrik, and B. Kaplan. 2001. Survival Improvement among Patients with End-Stage Renal Disease: Trends over Time for Transplant Recipients and Wait-Listed Patients. Journal of the American Society of Nephrology 12: 1293-96.
27. Perrone, R., R. Ruthazer, and N. Terrin. 2001. Survival after End-Stage Renal Disease in Autosomal Dominant Polycystic Kidney Disease: Contribution of Extrarenal Complications to Mortality. American Journal of Kidney Disease 38(4): 777-84.
28. Rabbat, C., K. Thorpe, D. Russell, and D. Churchill. 2000. Comparison of Mortality Risk for Dialysis Patients and Cadaveric First Renal Transplant Recipients in Ontario, Canada. Journal of the American Society of Nephrology 11: 917-22.
29. Ravine, D., R. Walker, R. Gibson, S. Forrest, R. Richards, K. Friend, L. Sheffield, P. Kincaid-Smith, and D. Danks. 1992. Phenotype and Genotype Heterogeneity in Autosomal Dominant Polycystic Kidney Disease. Lancet 340: 1330-33.
30. Subramanian, K., J. Lemaire, J. C. Hershey, M. V. Pauly, K. Armstrong, and D. A. Asch. 2000. Estimating Adverse Selection Costs from Genetic Testing for Breast and Ovarian Cancer: The Case of Life Insurance. Journal of Risk and Insurance 66: 531-50.
31. Tsakiris, D., E. Jones, D. Brigs, C. Elinder, O. Mehls, S. Mendel, G. Piccoli, S. Rigden, J. Dos Santos, K. Simpson, and Y. Vanrenterghem. 1999. Deaths within 90 Days from Starting Renal Replacement Therapy in the ERA-EDTA Registry between 1990 and 1992. Nephrology Dialysis Transplantation 14: 2343-50.
32. U.K. TRANSPLANT. 2002. U.K. Transplant Annual Report 2001. U.K. Transplant-Bristol, U.K. Renal Registry.
33. United States Renal Diseases System. 1999. Annual Report of the United States Renal Diseases System. USRDS.
34. Watson, M., and V. Torres. 1996. Polycystic Kidney Disease. Oxford: Oxford University Press.
35. Wolfe, R., V. Ashby, E. Milford, A. Ojo, R. Ettenger, L. Agodoa, P. Held, and F. Port. 1999. Comparison of Mortality in All Patients on Dialysis, Patients on Dialysis Awaiting Transplantation and Recipients of a First Cadaveric Transplant. New England Journal of Medicine 341: 1725-30.